Clinical and bacteriological efficacy in treatment of acute exacerbations of chronic bronchitis with cefditoren-pivoxil versus cefuroxime-axetil

Antimicrobial Agents and Chemotherapy

Volumn 50, Issue 5, 2006, Pages 1762-1767

  Alvarez Sala, Jose Luis ^a   Kardos, Peter ^b   Martínez Beltrán, Jesús ^c   Coronel, Pilar ^d   Aguilar, Lorenzo ^e  

^a HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^b Group Practice and Centre for Allergy Respiratory and Sleep Medicine   (Germany)

^c HOSPITAL RAMÓN Y CAJAL   (Spain)

^d Celltech Pharma   (Spain)

^e SCHOOL OF MEDICINE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENERGIC RECEPTOR STIMULATING AGENT; CEFDITOREN PIVOXIL; CEFUROXIME AXETIL; CORTICOSTEROID; MUSCARINIC RECEPTOR BLOCKING AGENT; PLACEBO;

ABDOMINAL PAIN; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CHRONIC BRONCHITIS; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DIAPHORESIS; DIARRHEA; DISEASE EXACERBATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DYSPNEA; FEMALE; FOLLOW UP; FORCED EXPIRATORY VOLUME; HAEMOPHILUS INFLUENZAE; HAEMOPHILUS PARAINFLUENZAE; HEADACHE; HEARTBURN; HUMAN; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; MORAXELLA CATARRHALIS; MULTICENTER STUDY; NAUSEA; PRIORITY JOURNAL; SIDE EFFECT; SPUTUM; STREPTOCOCCUS PNEUMONIAE; SYMPTOM; UREA NITROGEN BLOOD LEVEL; VOMITING; WHEEZING;

ACUTE DISEASE; ADMINISTRATION, ORAL; AGED; ANTI-BACTERIAL AGENTS; BRONCHITIS, CHRONIC; CEFUROXIME; CEPHALOSPORINS; CONFIDENCE INTERVALS; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HAEMOPHILUS INFLUENZAE; HUMANS; MALE; MIDDLE AGED; SPUTUM; TIME FACTORS; TREATMENT OUTCOME;

EID: 33646461527     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.50.5.1762-1767.2006     Document Type: Article

References (30)

1. Anthonisen, N. R., J. Manfreda, C. P. Warren, E. S. Hershfield, G. K. Harding, and N. A. Nelson. 1987. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann. Intern. Med. 106:196-204.
2. Appelbaum, P. C., S. H. Gillespie, C. J. Burley, and G. S. Tillotson. 2004. Antimicrobial selection for community-acquired lower respiratory tract infections in the 21st century: a review of gemifloxacin. Int. J. Antimicrob. Agents. 23:533-546.
3. Ball, P., F. Baquero, O. Cars, T. File, J. Garau, K. Klugman, D. E. Low, E. Rubinstein, R. Wise, and the Consensus Group on Resistance and Prescribing in Respiratory Tract Infection. 2002. Antibiotic therapy of community respiratory tract infections: strategies for optimal outcomes and minimized resistance emergence. J. Antimicrob. Chemother. 49:31-40.
4. Ball, P., and B. Make. 1998. Acute exacerbations of chronic bronchitis: an international comparison. Chest 113(3 Suppl.):199S-204S.
5. Barberán, J., M. J. Giménez, L. Aguilar, and J. Prieto. 2004. Evidencia científica y concepción global del tratamiento empírico de la infección de vías respiratorias bajas en la comunidad. Rev. Esp. Quimioter. 17:317-324.
6. Craig, W. A. 1998. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin. Infect. Dis. 26:1-12.
7. Farrington, C. F., and G. Manning. 1990. Test statistics and sample size formulae for comparative binomial trials with null hypothesis of non-zero risk difference or non-unity relative risk. Stat. Med. 9:1447-1454.
8. Garcia-Rey, C., L. Aguilar, F. Baquero, J. Casal, and R. Dal-Re. 2002. Importance of local variations in antibiotic consumption and geographical differences of erythromycin and penicillin resistance in Streptococcus pneumoniae. J. Clin. Microbiol. 40:159-164.
9. Garcia-Rey, C., A. Fenoll, L. Aguilar, and J. Casal. 2004. Effect of social and climatological factors on antimicrobial use and Streptococcus pneumoniae resistance in different provinces in Spain. J. Antimicrob. Chemother. 54:465-471.
10. Granizo, J. J., L. Aguilar, J. Casal, C. Garcia-Rey, R. Dal-Re, and F. Baquero. 2000. Streptococcus pneumoniae resistance to erythromycin and penicillin in relation to macrolide and beta-lactam consumption in Spain (1979-1997). J. Antimicrob. Chemother. 46:767-773.
11. Grossman, R. F. 1997. Guidelines for the treatment of acute exacerbations of chronic bronchitis. Chest 112(6 Suppl.):310S-313S.
12. Guest, N., and C. E. Langan. 1998. Comparison of the efficacy and safety of a short course of ceftibuten with that of amoxycillin/davulanate in the treatment of acute exacerbations of chronic bronchitis. Int. J. Antimicrob. Agents. 10:49-54.
13. Gump, D. W., C. A. Phillips, B. R. Forsyth, K. McIntosh, K. R. Lamborn, and W. H. Stouch. 1976. Role of infection in chronic bronchitis. Am. Rev. Respir. Dis. 113:465-74.
14. Jorgensen, A. F., J. Coolidge, P. A. Pedersen, K. P. Petersen, S. Waldorff, and E. Widding. 1992. Amoxicillin in treatment of acute uncomplicated exacerbations of chronic bronchitis. A double-blind, placebo-controlled multicentre study in general practice. Scand. J. Prim. Health Care 10:7-11.
15. Madison, J. M., and R. S. Irwin. 1998. Chronic obstructive pulmonary disease. Lancet 352:467-473.
16. Miravitlles, M., C. Murio, T. Guerrero, R. Gisbert, and the DAFNE Study Group. 2002. Decisiones sobre Antibioticotcrapia y Farmacoeconomia en la EPOC. Pharmacoeconomic evaluation of acute exacerbations of chronic bronchitis and COPD. Chest 121:1449-1455.
17. Nicolson, P., and P. Anderson. 2000. The patient's burden: physical and psychological effects of acute exacerbations of chronic bronchitis. J. Antimicrob. Chemother. 45:25-32.
18. Pauwels, R. A., A. S. Buist, P. M. Calverley, C. R. Jenkins, S. S. Hurd, and the GOLD Scientific Committee. 2001. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. Am. J. Respir. Crit. Care Med. 163:1256-1276.
19. Pechere, J. C., and L. Lacey. 2000. Optimizing economic outcomes in antibiotic therapy of patients with acute bacterial exacerbations of chronic bronchitis. J. Antimicrob. Chemother. 45:19-24.
20. Perez-Trallero, E., C. Garcia-de-la-Fuente, C. Garcia-Rey, F. Baquero, L. Aguilar, R. Dal-Re, J. Garcia-de-Lomas, and the Spanish Surveillance Group for Respiratory Pathogens. 2005. Geographical and ecological analysis of resistance, coresistance and coupled-resistance to antimicrobials in and between respiratory pathogenic bacteria in Spain. Antimicrob. Agents Chemother. 49:1965-1972.
21. Pfaller, M. A., A. F. Ehrhardt, and R. N. Jones. 2001. Frequency of pathogen occurrence and antimicrobial susceptibility among community-acquired respiratory tract infections in the respiratory surveillance program study: microbiology from the medical office practice environment. Am. J. Med. 111(Suppl. 9A):4S-12S
22. Saint, S., S. Bent, E. Vittinghoff, and D. Grady. 1995. Antibiotics in chronic obstructive pulmonary disease exacerbations. A meta-analysis. JAMA 273:957-960.
23. Sethi, S., J. Breton, and B. Wynne. 2005. Efficacy and safety of pharmacokinetically enhanced amoxicillin-clavulanate at 2,000/125 milligrams twice daily for 5 days versus amoxicillin-clavulanate at 875/125 milligrams twice daily for 7 days in the treatment of acute exacerbations of chronic bronchitis. Antimicrob. Agents Chemother. 49:153-160.
24. Sethi, S., N. Evans, B. J. Grant, and T. F. Murphy. 2002. New strains of bacteria and exacerbations of chronic obstructive pulmonary disease. N. Engl. J. Med. 347:465-171.
25. Soriano, F. 2004. Importancia de los parámetros farmacocinéticos y farmacodinámicos en la elección del tratamiento antimicrobiano de la infección respiratoria. Med. Clin. Monogr. (Barcelona) 5:6-11.
26. Soriano, F., J. J. Granizo, P. Coronel, M. Gimeno, E. Rodenas, M. Gracia, C. Garcia, R. Fernandez-Roblas, J. Esteban, and I. Gadea. 2004. Antimicrobial susceptibility of Haemophilus influenzae, Haemophilus parainfluenzae and Moraxella catarrhalis isolated from adult patients with respiratory tract infections in four southern European countries. The ARISE project. Int. J. Antimicrob. Agents 23:296-299.
27. Soriano, F., J. J. Granizo, A. Fenoll, M. Gracia, R. Fernandez-Roblas, J. Esteban, I. Gadea, P. Coronel, M. Gimeno, E. Rodenas, and F. Santos. 2003. Antimicrobial resistance among clinical isolates of Streptococcus pneumoniae isolated in four southern European countries (ARISE project) from adult patients: results from the cefditoren surveillance program. J. Chemother. 15:107-112.
28. Torres, A. 2004. Tratamiento antibiótico de las agudizaciones de la enfermedad pulmonar obstructiva crónica. Papel de la nueva formulación de liberación prolongada de amoxicilina-ácido clavulánico 2.000/125 mg. Med. Clin. Monogr. (Barcelona) 5:37-41.
29. Wellington, K., and M. P. Curran. 2004. Cefditoren pivoxil: a review of its use in the treatment of bacterial infections. Drugs 64:2597-2618.
30. Wilson, R., L. Allegra, G. Huchon, J. L. Izquierdo, P. Jones, T. Schaberg, P. P. Sagnier, and the MOSAIC Study Group. 2004. Short-term and long-term outcomes of moxifloxacin compared to standard antibiotic treatment in acute exacerbations of chronic bronchitis. Chest 125:953-964.